Skip to main content

Table 2 Eradication of Mycoplasma genitalium DNA during treatment with josamycin in 46 males with urethritis

From: Treatment efficacy, treatment failures and selection of macrolide resistance in patients with high load of Mycoplasma genitalium during treatment of male urethritis with josamycin

Bacterial load pre-treatment M. genitaliumDNA concentration (geq/mL [log10]) No. (%) ofM. genitaliumpositive patients
0 d/t 3 d/t 8 d/t 2 d/at 10-14 d/at
Low ≤4 10 (100) 3 (30) 0 (0) 0 (0) 0 (0)
Moderate >4 - <6 29 (100) 15 (51.7)b 3 (10.3) 2 (6.9)d 0 (0)
High ≥6 6 (100) 5 (83.3) 2 (33.3)c 3 (50) 3 (50)
Total no. of patients examined 45a 45 45 45 14e
  1. geq/mL (log10), log10 of genome equivalents/mL; d/t, days of treatment; d/at, days after completed treatment.
  2. aSample from one patient was not available. At 3 d/t, this patient had 3.1 geq/mL [log10], and at the three subsequent visits he was M. genitalium negative.
  3. bSample from one patient was not available. This patient was asymptomatic, M. genitalium negative but demonstrated microscopic signs of urethritis on the three subsequent visits.
  4. cSample from one patient was not available. This was treatment failure A, see Table 3.
  5. dSample from one patient was not available. The patient reported to be asymptomatic on the phone and at 3 d/t and 8 d/t, no symptoms, signs or M. genitalium DNA was detected.
  6. eThirty-two patients did not attend. However, all of the non-attending patients were M. genitalium negative already at earlier visits (both at 8 d/t and 2 d/at) and also reported to be completely asymptomatic on phone.